Stockreport

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences, Inc.  (MBX) 
PDF Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising appro [Read more]